RxDoctor Payments Data

Harleen Kaur, MD

Family Medicine · Parlin, NJNPI 1922267012

Payments from drug & device makers

$863in general payments, 2019–2025

Across 35 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$136
  • Gilead$111
  • AstraZeneca$93
  • Ardelyx, Inc.$75
  • AbbVie$66
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$64
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$863 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$153,593
Medicare patients
126
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$91,288
JanuviaSitagliptin Phosphate39$47,873
EliquisApixaban17$26,933
Budesonide ErBudesonide11$25,001
TradjentaLinagliptin25$20,087
Breo ElliptaFluticasone/Vilanterol37$16,812
JanumetSitagliptin Phos/Metformin Hcl15$9,496
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$5,424
Rosuvastatin Calcium292$3,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,067
Albuterol Sulfate HfaAlbuterol Sulfate71$2,005
Atorvastatin Calcium281$1,746
Levothyroxine Sodium195$1,450
Omeprazole94$1,410
Gabapentin75$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$26,93317 claims
GSKBreo Ellipta$15$16,81237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Parlin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →